Pulmonary Arterial Hypertension

Detailed Overview

PAH is Group 1 of the WHO clinical classification of pulmonary hypertension. The remodeling of small pulmonary arteries causes a severe restriction in blood flow through the lungs. This increases right ventricular afterload, prompting compensatory right ventricular hypertrophy, which eventually fails, causing cor pulmonale. PAH is distinct from other forms of PH (like those secondary to COPD or left-sided heart failure) because it represents a primary intrinsic disease of the pulmonary vasculature. Without targeted vasodilatory and anti-proliferative therapy, median survival is under 3 years.

Epidemiology & Demographics

Incidence is 2-5 cases per 1 million adults per year. Prevalence is 15-50 cases per 1 million. Idiopathic PAH has a female predominance (ratio 3:1 to 4:1) with a mean age of diagnosis around 50 years, though heritable forms often present in the 30s.

Etiological Mechanism

Mutations in the BMPR2 gene account for ~75% of familial PAH cases and up to 25% of sporadic (idiopathic) cases. It can also be associated with connective tissue diseases (especially Systemic Sclerosis), HIV infection, portal hypertension, and exposure to certain drugs/toxins (e.g., aminorex, fenfluramines, methamphetamines).

Primary Causes

Idiopathic (IPAH), Heritable (BMPR2, ALK-1 mutations), Drug/Toxin-induced (anorexigens), Connective Tissue Diseases (Systemic Sclerosis, SLE), HIV infection, Portal Hypertension, Congenital Heart Disease (Eisenmenger syndrome), and Schistosomiasis.

• Genetics: Family history of PAH or presence of BMPR2 mutation.
• Systemic Sclerosis: Patients with limited cutaneous systemic sclerosis (CREST syndrome) have a 10-15% lifetime risk of developing PAH.
• Methamphetamine Use: Significant emerging risk factor due to direct toxic effects on pulmonary endothelium.
• Liver Disease: Portal hypertension can lead to portopulmonary hypertension.

Endothelial injury leads to an imbalance in vasoactive mediators: an overproduction of vasoconstrictors/mitogens (endothelin-1, thromboxane A2) and a deficiency of vasodilators/antiproliferative agents (nitric oxide, prostacyclin). This triggers pulmonary artery smooth muscle cell (PASMC) proliferation, endothelial cell apoptosis followed by hyperproliferation, and extracellular matrix deposition. These processes cause medial hypertrophy, intimal fibrosis, and the formation of plexiform lesions (complex vascular out-pouchings). The resultant narrowing increases pulmonary vascular resistance (PVR). The right ventricle (RV) initially hypertrophies to maintain cardiac output, but eventually dilates, leading to tricuspid regurgitation, reduced RV ejection fraction, and systemic venous congestion.

Characteristic Clinical Presentation

• Exertional Dyspnea: The most common and earliest symptom; shortness of breath initially only during physical activity.
• Fatigue: Due to fixed cardiac output unable to meet peripheral oxygen demands.
• Exertional Syncope: Fainting during exercise because the RV cannot push blood past the high pulmonary resistance to fill the left heart, dropping systemic blood pressure.
• Peripheral Edema: Swelling in legs and abdomen due to right heart failure.

Physical Examination Signs

• Loud P2
• Right Ventricular Heave
• Elevated JVP

• Cor Pulmonale: Right ventricular failure secondary to pulmonary hypertension.
• Arrhythmias: Atrial flutter or fibrillation due to right atrial dilation.
• Hemoptysis: Rupture of hypertrophied bronchial arteries, can be massive and fatal.

Diagnostic Criteria & Guidelines

Right Heart Catheterization (RHC) is the gold standard and required for diagnosis. Criteria: Mean pulmonary arterial pressure (mPAP) > 20 mmHg at rest, Pulmonary Capillary Wedge Pressure (PCWP) <= 15 mmHg, and Pulmonary Vascular Resistance (PVR) >= 3 Wood Units. Vasoreactivity testing with inhaled nitric oxide is performed during RHC.

Differential Diagnosis

• Group 2 PH (Left Heart Disease)
• Group 3 PH (COPD, Interstitial Lung Disease)
• Group 4 PH (Chronic Thromboembolic Pulmonary Hypertension - CTEPH)
• Asthma
• Pulmonary Embolism (acute)

Laboratory Tests & Biomarkers

• BNP or NT-proBNP: Elevated (e.g., NT-proBNP > 300 pg/mL) correlating with the severity of right ventricular strain.
• ANA: Positive in about 30% of idiopathic cases and high in connective tissue disease associated PAH.
• Liver Function Tests: Elevated bilirubin and transaminases in severe right heart failure (congestive hepatopathy).

Imaging Modalities & Findings

• Echocardiography: Right ventricular dilation and hypertrophy, flattened or D-shaped intraventricular septum during systole, elevated estimated right ventricular systolic pressure (RVSP > 35 mmHg).
• V/Q Scan: Normal or mottled appearance; performed to rule out CTEPH (which would show mismatched perfusion defects).

• WHO Functional Class I
  PAH present, but no limitation of physical activity. Ordinary physical activity does not cause dyspnea or fatigue.
• WHO Functional Class II
  Slight limitation of physical activity. Comfortable at rest, but ordinary activity causes undue dyspnea or fatigue.
• WHO Functional Class III
  Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms.
• WHO Functional Class IV
  Inability to carry out any physical activity without symptoms. Signs of right heart failure. Dyspnea at rest.

Second-Line & Adjunctive Therapy

For WHO FC IV or rapid progression: Addition of a prostacyclin analogue. Epoprostenol via continuous intravenous infusion (starting at 2 ng/kg/min and titrating up based on tolerance), or Treprostinil (IV/SC or inhaled).

Surgical & Procedural Management

Bilateral lung transplantation is the definitive treatment for severe, medically refractory PAH. Atrial septostomy may be performed as a palliative bridge to transplant to offload the failing right ventricle (creates right-to-left shunt, accepting hypoxia to improve cardiac output).

Recommended Lifestyle Changes

• Strict sodium restriction (< 2g/day) to manage volume overload and edema.
• Avoidance of heavy physical exertion or isometric exercises, though supervised cardiopulmonary rehabilitation is recommended.
• Avoidance of high altitudes and commercial air travel without supplemental oxygen.

Patient Counseling & Advice

Pregnancy carries a 30-50% maternal mortality risk in PAH; strict contraception (progesterone-only or IUDs, avoiding estrogen) is absolutely mandatory. Inform patients about the complexity of managing IV prostacyclins if prescribed (risk of line infections, rebound severe PH if pump stops).

Follow-Up & Monitoring Schedule

Echocardiogram and NT-proBNP every 3-6 months. 6-Minute Walk Test (6MWT) at every clinic visit to assess functional capacity. Repeat Right Heart Catheterization if clinical status deteriorates.

Preventive Strategies

Screening high-risk populations (e.g., annual echocardiogram for patients with Systemic Sclerosis or known BMPR2 mutations) for early detection. No definitive prevention for idiopathic cases.

Despite modern combination therapy, PAH remains incurable. The 5-year survival rate is approximately 60-65%. Prognosis is significantly better for responders to calcium channel blockers (a very small subset) and worse for those associated with connective tissue diseases.